Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811993 · ClinicalTrials.gov registry record · Phase 1
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT00811993 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 104 participants.
The verdict
NCT00811993, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There are 3 subsets of patients who are eligible for the study: untreated, treated and requiring further treatment, or treated and failed and for whom adding R1507 represents a suitable treatment for their disease. All regimens will first test doses of R1507 which are less than the maximally administered dose, and if tolerated, the dose will be escalated in subsequent patients. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
Interventions
- DRUG carboplatin
- DRUG capecitabine [Xeloda]
- DRUG RG1507
- DRUG bevacizumab [Avastin]
- DRUG RO1507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811993
The ClinicalTrials.gov registry entry for NCT00811993 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00811993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00811993 about?
NCT00811993 is a clinical study titled "A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors". This study will evaluate the safety and tolerability of R1507 in combination with 12 distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There are 3 subsets of patients who are ...
What is the current status of trial NCT00811993?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2009-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00811993?
The interventions under investigation include: carboplatin (DRUG), capecitabine [Xeloda] (DRUG), RG1507 (DRUG), bevacizumab [Avastin] (DRUG), RO1507 (DRUG).
Who is sponsoring clinical trial NCT00811993?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.